• Search
  • Advanced Search

Review

January 5, 2023


Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, et al.
Clin Mol Hepatol. 2023;29(2):197-205.

Hepatocellular carcinoma (HCC) is a major cause of death in many countries, including South Korea. To provide useful and sensible advice for clinical management of patients with HCC, the Korean...

Review

December 22, 2022


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, et al.
Clin Mol Hepatol. 2023;29(2):206-216.

Liver cancer is the fourth most prevalent and the second most lethal cancer in China. Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma (HCC). Liver...

Review

December 28, 2022


Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, et al.
Clin Mol Hepatol. 2023;29(2):217-229.

Hepatocellular carcinoma (HCC) is a major public health burden in Hong Kong, and chronic hepatitis B is the most common HCC etiology in our region. With the high case load,...

Review

January 30, 2023


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, et al.
Clin Mol Hepatol. 2023;29(2):230-241.
Hepatocellular carcinoma (HCC) is the fourth most common cancer and the second leading cause of cancer-related death in Taiwan. The Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan...

Review

March 20, 2023


Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, et al.
Clin Mol Hepatol. 2023;29(2):242-251.

Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC...

Review

March 10, 2023


Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.

Hepatocellular carcinoma (HCC) is highly prevalent and the third most common cause of cancer-related death in Asia. In contrast to the West, the main etiology of HCC in many Asian...

Review

January 19, 2023


The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, et al.
Clin Mol Hepatol. 2023;29(2):263-276.

Chronic hepatitis B infection is a major public health challenge. With the advancement in technology, various components of the viral cycle can now be measured in the blood to assess...

Review

January 30, 2023


Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, et al.
Clin Mol Hepatol. 2023;29(2):277-292.
Even though the combined use of ultrasound (US) and alpha-fetoprotein (AFP) is recommended for the surveillance of hepatocellular carcinoma (HCC), the utilization of AFP has its challenges, including accuracy dependent...

Review

February 1, 2023


Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, et al.
Clin Mol Hepatol. 2023;29(2):293-319.

Hepatocellular carcinoma (HCC) is one of the most common and deadly cancers worldwide and is characterized by complex molecular carcinogenesis. Neuropilins (NRPs) NRP1 and NRP2 are the receptors of multiple...

Review

February 1, 2023


Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):320-331.

The prevalence of metabolic dysfunction-associated fatty liver disease (MAFLD) has increased among the general population and chronic hepatitis B (CHB) patients worldwide. Although fatty liver disease is a well-known risk...

Original Article

November 21, 2022


Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, et al.
Clin Mol Hepatol. 2023;29(2):417-432.

Background/Aims: Immune and inflammatory cells respond to multiple pathological hits in the development of nonalcoholic steatohepatitis (NASH) and fibrosis. Relatively little is known about how their type and function change...

Original Article

January 4, 2023


Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, et al.
Clin Mol Hepatol. 2023;29(2):433-452.

Background/Aims: Global distribution of dominant liver cancer aetiologies has significantly changed over the past decades. This study analyzed the updated temporal trends of liver cancer aetiologies and sociodemographic status in...

Original Article

February 1, 2023


Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, et al.
Clin Mol Hepatol. 2023;29(2):453-464.

Background/Aims: Cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC), and patients with cirrhosis are recommended to receive semiannual surveillance for early HCC detection. However, early cirrhosis is...

Original Article

February 20, 2023


Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
Jing Yang, Xujiao Tang, Zhu Liang, et al.
Clin Mol Hepatol. 2023;29(2):465-481.

Background/Aims: Disrupted bile acid regulation and accumulation in the liver can contribute to progressive liver damage and fibrosis. However, the effects of bile acids on the activation of hepatic stellate...

Original Article

January 5, 2023


Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, et al.
Clin Mol Hepatol. 2023;29(2):482-495.

Background/Aims: The histologic status of the immune-tolerant (IT) phase of chronic hepatitis B relative to long-term outcomes is unclear. This study aimed to discover how the serological criteria currently in...

Original Article

March 6, 2023


Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, et al.
Clin Mol Hepatol. 2023;29(2):496-509.

Background/Aims: We used next-generation sequencing (NGS) to analyze resistance-associated substitutions (RASs) and retreatment outcomes in patients with chronic hepatitis C virus (HCV) infection who failed direct-acting antiviral agent (DAA) treatment...
Current Issue
Volume 29(2); Apr 2023
Review
1761
Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
Clin Mol Hepatol. 2023;29(2):197-205.   Published online January 5, 2023
View: 1573   Download: 145  Citations: 3
1755
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective
Diyang Xie, Jieyi Shi, Jian Zhou, Jia Fan, Qiang Gao
Clin Mol Hepatol. 2023;29(2):206-216.   Published online December 22, 2022
View: 1793   Download: 253  Citations: 2
1758
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective
Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(2):217-229.   Published online December 28, 2022
View: 1666   Download: 164  Citations: 3
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):230-241.   Published online January 30, 2023
View: 1845   Download: 222  Citations: 4
1813
Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori Koga, Hideki Iwamoto, Hiroyuki Suzuki, Shigeo Shimose, Masahito Nakano, Takumi Kawaguchi
Clin Mol Hepatol. 2023;29(2):242-251.   Published online March 20, 2023
View: 1180   Download: 121
1797
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong-Won Park
Clin Mol Hepatol. 2023;29(2):252-262.   Published online March 10, 2023
View: 1180   Download: 128
1764
The role of different viral biomarkers on the management of chronic hepatitis B
Lung-Yi Mak, Rex Wan-Hin Hui, James Fung, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2023;29(2):263-276.   Published online January 19, 2023
View: 1395   Download: 172  Citation: 1
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
Do Young Kim, Bao Nguyen Toan, Chee-Kiat Tan, Irsan Hasan, Lyana Setiawan, Ming-Lung Yu, Namiki Izumi, Nguyen Nguyen Huyen, Pierce Kah-Hoe Chow, Rosmawati Mohamed, Stephen Lam Chan, Tawesak Tanwandee, Teng-Yu Lee, Thi Thanh Nguyen Hai, Tian Yang, Woo-Chang Lee, Henry Lik Yuen Chan
Clin Mol Hepatol. 2023;29(2):277-292.   Published online January 30, 2023
View: 1782   Download: 267  Citations: 3
1769
Neuropilins as potential biomarkers in hepatocellular carcinoma: a systematic review of basic and clinical implications
Paula Fernández-Palanca, Tania Payo-Serafín, Carolina Méndez-Blanco, Beatriz San-Miguel, María J. Tuñón, Javier González-Gallego, José L. Mauriz
Clin Mol Hepatol. 2023;29(2):293-319.   Published online February 1, 2023
View: 1148   Download: 74
1770
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Shang-Chin Huang, Chun-Jen Liu
Clin Mol Hepatol. 2023;29(2):320-331.   Published online February 1, 2023
View: 1423   Download: 191  Citation: 1
Editorial
What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
Min Kyung Park, Yoon Jun Kim
Clin Mol Hepatol. 2023;29(2):332-334.   Published online March 16, 2023
View: 655   Download: 21
Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
Do Young Kim
Clin Mol Hepatol. 2023;29(2):335-338.   Published online March 20, 2023
View: 693   Download: 28
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Shan Shan, Jidong Jia
Clin Mol Hepatol. 2023;29(2):339-341.   Published online March 16, 2023
View: 738   Download: 37
Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen
Clin Mol Hepatol. 2023;29(2):342-344.   Published online March 16, 2023
View: 744   Download: 32
The prime time for management of hepatocellular carcinoma in Hong Kong
Landon L. Chan, Stephen L. Chan
Clin Mol Hepatol. 2023;29(2):345-348.   Published online March 9, 2023
View: 681   Download: 29
Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
Shen-Yung Wang
Clin Mol Hepatol. 2023;29(2):349-351.   Published online March 20, 2023
View: 746   Download: 28
Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
San-Chi Chen
Clin Mol Hepatol. 2023;29(2):352-354.   Published online March 20, 2023
View: 718   Download: 34
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):355-357.   Published online March 9, 2023
View: 667   Download: 27
1802
The current trends in the health burden of primary liver cancer across the globe
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2023;29(2):358-362.   Published online March 14, 2023
View: 757   Download: 30
1795
The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
Moon Haeng Hur, Jeong-Hoon Lee
Clin Mol Hepatol. 2023;29(2):363-366.   Published online March 9, 2023
View: 659   Download: 43
Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
Joo Hyun Oh, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):367-370.   Published online March 20, 2023
View: 631   Download: 35
Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
Eileen Laurel Yoon, Dae Won Jun
Clin Mol Hepatol. 2023;29(2):371-373.   Published online March 14, 2023
View: 725   Download: 43
The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clin Mol Hepatol. 2023;29(2):374-376.   Published online March 6, 2023
View: 625   Download: 30
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Ho Soo Chun, Minjong Lee
Clin Mol Hepatol. 2023;29(2):377-380.   Published online March 9, 2023
View: 663   Download: 40
Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
Heejoon Jang, Won Kim
Clin Mol Hepatol. 2023;29(2):381-383.   Published online March 9, 2023
View: 686   Download: 35
Implications of comorbidities in nonalcoholic fatty liver disease
Sherlot Juan Song, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2023;29(2):384-389.   Published online March 14, 2023
View: 802   Download: 45
Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
Philipp Kasper, Münevver Demir, Hans-Michael Steffen
Clin Mol Hepatol. 2023;29(2):390-393.   Published online March 20, 2023
View: 647   Download: 22
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Lynna Alnimer, Mazen Noureddin
Clin Mol Hepatol. 2023;29(2):394-397.   Published online April 1, 2023
View: 708   Download: 39
Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
Maamon Basheer, Mohamed Naffaa, Nimer Assy
Clin Mol Hepatol. 2023;29(2):398-400.   Published online February 13, 2023
View: 754   Download: 68
Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
Kee-Huat Chuah, Wah-Kheong Chan
Clin Mol Hepatol. 2023;29(2):401-403.   Published online February 28, 2023
View: 682   Download: 29
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
Clin Mol Hepatol. 2023;29(2):404-407.   Published online March 14, 2023
View: 765   Download: 32
The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
Ji-Won Park, Ki Tae Suk
Clin Mol Hepatol. 2023;29(2):408-410.   Published online March 16, 2023
View: 639   Download: 39
How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
Byeong Geun Song, Dong Hyun Sinn
Clin Mol Hepatol. 2023;29(2):411-413.   Published online March 6, 2023
View: 632   Download: 24
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
Young-Joo Jin
Clin Mol Hepatol. 2023;29(2):414-416.   Published online February 28, 2023
View: 2433   Download: 48
Original Article
1772
Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease
Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi
Clin Mol Hepatol. 2023;29(2):417-432.   Published online November 21, 2022
View: 1723   Download: 97  Citation: 1
1760
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study
Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith
Clin Mol Hepatol. 2023;29(2):433-452.   Published online January 4, 2023
View: 1684   Download: 139  Citations: 4
1771
Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma
Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol. 2023;29(2):453-464.   Published online February 1, 2023
View: 1174   Download: 80
1782
Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun
Clin Mol Hepatol. 2023;29(2):465-481.   Published online February 20, 2023
View: 1066   Download: 100  Citation: 1
1763
Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase
Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim
Clin Mol Hepatol. 2023;29(2):482-495.   Published online January 5, 2023
View: 1279   Download: 108  Citations: 4
1789
Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea
Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong
Clin Mol Hepatol. 2023;29(2):496-509.   Published online March 6, 2023
View: 951   Download: 77
Letter to the Editor
Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”
Chia-Ming Chu, Yun-Fan Liaw
Clin Mol Hepatol. 2023;29(2):510-512.   Published online January 30, 2023
View: 699   Download: 37
Correspondence
Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”
Jeong-Ju Yoo, Sang Gyune Kim
Clin Mol Hepatol. 2023;29(2):513-515.   Published online February 15, 2023
View: 624   Download: 26
Snapshot
1783
Systemic therapy in advanced hepatocellular carcinoma
Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang
Clin Mol Hepatol. 2023;29(2):516-519.   Published online February 20, 2023
View: 941   Download: 92  Citations: 3

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 321
TOTAL : 1299008
Close layer